The AMARANTH and DAYBREAK-ALZ randomized clinical trials assess whether lanabecestat slows the progression of Alzheimer disease compared with placebo in patients with early Alzheimer disease or mild Alzheimer disease dementia.
from journals https://ift.tt/37FS0MG
from journals https://ift.tt/37FS0MG
Comments
Post a Comment